Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing demand for effective anthrax treatment
3.2.1.2 Rising healthcare investments
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness for diagnostic tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Inhalation anthrax
5.3 Cutaneous anthrax
5.4 Gastrointestinal anthrax
5.5 Injection anthrax
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Antibiotics
6.3 Immunoglobulins
6.4 Combination therapy
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Parenteral
7.3 Oral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alembic Pharmaceuticals Limited
10.2 Almirall, LLC
10.3 Bayer AG
10.4 Emergent BioSolutions
10.5 GlaxoSmithKline plc
10.6 GC Biopharma, corp.
10.7 Integrated Bio Therapeutics Inc.
10.8 Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
10.9 Paratek Pharmaceuticals, Inc.
10.10 Pfizer Inc.
10.11 Porton Biopharma
10.12 Sanofi SA
10.13 Sun Pharmaceutical Industries Ltd.
10.14 Takeda Pharmaceutical Company Limited
10.15 Teva Pharmaceutical Industries Ltd.
